[Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)]

58 women with metastatic breast cancer, non-responsive to hormone therapy, were treated with a modified CMF regimen. After progression the combination of adriamycin and vincristine was used. With CMF the response rate was 41% (10% complete remissions, 31% partial remissions), 38% showed no change, whilst progression of the disease was observed in only 21% of patients. The median duration of remission was about 8 months. Progression of the disease was treated by a combination of adriamycin and vincristine and remissions were obtained in 24% of cases. The median survival time of our patients from the time of tumour metastasis was 18.6 months and was dependent on the results of treatment.